The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Protein Arginine Methyltransferase 5 Accelerates Tumor Growth by Arginine Methylation of the Tumor Suppressor Programmed Cell Death 4
Open accessAbstract
Programmed cell death 4 (PDCD4) has been described as a tumor suppressor, with high expression correlating with better outcomes in a number of cancer types. Yet a substantial number of cancer patients with high PDCD4 in tumors have poor survival, suggesting that oncogenic pathways may inhibit or change PDCD4 function. Here, we explore the significance of PDCD4 in breast cancer and identify protein arginine methyltransferase 5 (PRMT5) as a cofactor that radically alters PDCD4 function. Specifically, we find that coexpression of PDCD4 and PRMT5 in an orthotopic model of breast cancer causes accelerated tumor growth and that this growth phenotype is dependent on both the catalytic activity of PRMT5 and a site of methylation within the N-terminal region of PDCD4. In agreement with the xenograft model, elevated PDCD4 expression was found to correlate with worse outcome within the cohort of breast cancer patients whose tumors contain higher levels of PRMT5. These results reveal a new cofactor for PDCD4 that alters its tumor suppressor functions and point to the utility of PDCD4/PRMT5 status as both a prognostic biomarker and a potential target for chemotherapy. Cancer Res; 71(16); 5579–87. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Asangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882
Yang, H.-S., Jansen, A. P., Komar, A. A., Zheng, X., Merrick, W. C., Costes, S., Lockett, S. J., Sonenberg, N., & Colburn, N. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.26-37.2003 · Cited by 494
Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis
Chen, Y., Knösel, T., Kristiansen, G., Pietas, A., Garber, M. E., Matsuhashi, S., Ozaki, I., & Petersen, I. (2003) · The Journal of Pathology · doi:10.1002/path.1378 · Cited by 265
Mudduluru, G., Medved, F., Grobholz, R., Jost, C., Gruber, A., Leupold, J. H., Post, S., Jansen, A., Colburn, N. H., & Allgayer, H. (2007) · Cancer · doi:10.1002/cncr.22983 · Cited by 196
Yang, H.-S., Jansen, A. P., Nair, R., Shibahara, K., Verma, A. K., Cmarik, J. L., & Colburn, N. H. (2001) · Oncogene · doi:10.1038/sj.onc.1204137 · Cited by 185
PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains
Suzuki, C., Garces, R. G., Edmonds, K. A., Hiller, S., Hyberts, S. G., Marintchev, A., & Wagner, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712235105 · Cited by 165
Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation
Yang, H.-S., Knies, J. L., Stark, C., & Colburn, N. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206433 · Cited by 160
Translation Inhibitor Pdcd4 Is Targeted for Degradation during Tumor Promotion
Schmid, T., Jansen, A. P., Baker, A. R., Hegamyer, G., Hagan, J. P., & Colburn, N. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1719 · Cited by 151
Crystal structure of the eIF4A–PDCD4 complex
Chang, J. H., Cho, Y. H., Sohn, S. Y., Choi, J. M., Kim, A., Kim, Y. C., Jang, S. K., & Cho, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808275106 · Cited by 120
Cited by
Protein arginine methyltransferases and cancer
Yang, Y., & Bedford, M. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3409 · Cited by 1,083
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1810 · Cited by 569
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
Stopa, N., Krebs, J. E., & Shechter, D. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1847-9 · Cited by 513
Protein arginine methylation: from enigmatic functions to therapeutic targeting
Wu, Q., Schapira, M., Arrowsmith, C. H., & Barsyte-Lovejoy, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00159-8 · Cited by 419
Crystal structure of the human PRMT5:MEP50 complex
Antonysamy, S., Bonday, Z., Campbell, R. M., Doyle, B., Druzina, Z., Gheyi, T., Han, B., Jungheim, L. N., Qian, Y., Rauch, C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209814109 · Cited by 362
Metadata
- Authors
- Powers, M. A., Fay, M. M., Factor, R. E., Welm, A. L., & Ullman, K. S.
- Venue
- Cancer Research
- Published
- 2011-08-11
- Volume
- 71
- Issue
- 16
- Pages
- 5579-5587
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1979003157
- Cited by
- 159
- References
- 10
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protein Arginine Methyltransferase 5 Accelerates Tumor Growth by Arginine Methylation of the Tumor Suppressor Programmed Cell Death 4. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-0458
- The paper
- Powers, M. A., Fay, M. M., Factor, R. E., Welm, A. L., & Ullman, K. S. (2011). Protein Arginine Methyltransferase 5 Accelerates Tumor Growth by Arginine Methylation of the Tumor Suppressor Programmed Cell Death 4. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-0458
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.